Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 2/20 | 0.30 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.30 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.30 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.30 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.30 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.30 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.30 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3507280 | 1.00 | SMN1; SMN2 (0.35) | SMN1; SMN2CA14CA12CA1CA2 | |
| SCHEMBL3614148 | 1.00 | SMN1; SMN2 (0.35) | SMN1; SMN2CA14CA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL22321971 | 0.98 | SMN1; SMN2 (0.34) | SMN1; SMN2CA14CA12 | |
| Hydrochloric Acid SCHEMBL3505000 | 0.98 | SMN1; SMN2 (0.34) | SMN1; SMN2CA14CA12 | |
| Hydrochloric Acid SCHEMBL3504997 | 0.98 | SMN1; SMN2 (0.34) | SMN1; SMN2CA14CA12 | |
| Hydrochloric Acid SCHEMBL5422423 | 0.98 | SMN1; SMN2 (0.34) | SMN1; SMN2CA14CA12 | |
| Hydrochloric Acid SCHEMBL5422419 | 0.98 | SMN1; SMN2 (0.34) | SMN1; SMN2CA14CA12 | |
| SCHEMBL918459 | 0.83 | NOS1 (0.43) | CA14CA12CA1CA2NOS1 | |
| SCHEMBL21841469 | 0.83 | NOS1 (0.43) | CA14CA12CA1CA2NOS1 | |
| SCHEMBL21841471 | 0.83 | NOS1 (0.43) | CA14CA12CA1CA2NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4622991-A2 | SYNTHESIS OF A CYCLIC PEPTIDE | Janssen Pharmaceutica NV (BE) | 2025-10-01 | — | — | EP | disclosed |
| CN-119613293-A | Method suitable for industrial production of Fmoc-Thr (tBu) -OH | 成都市科隆化学品有限公司 | 2025-03-14 | — | — | CN | disclosed |
| US-20240400525-A1 | 1,2,4-Oxadiazole Derivatives as Immunomodulators | AURIGENE ONCOLOGY LIMITED (IN) | 2024-12-05 | — | — | US | disclosed |
| US-12037321-B2 | 1,2,4-oxadiazole derivatives as immunomodulators | AURIGENE ONCOLOGY LIMITED (IN) | 2024-07-16 | — | — | US | disclosed |
| US-20240218014-A1 | SYNTHESIS OF A CYCLIC PEPTIDE | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-04 | — | — | US | disclosed |
| US-20240218014-A1 | SYNTHESIS OF A CYCLIC PEPTIDE | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-04 | — | — | US | disclosed |
| US-20240218014-A1 | SYNTHESIS OF A CYCLIC PEPTIDE | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-04 | — | — | US | disclosed |
| US-20230348493-A1 | COMPOUND FOR ADJUSTING ACTIVITY OF NMDA RECEPTOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | BEIJING GREATWAY PHARMACEUTICAL TECHNOLOGY CO. LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230348493-A1 | COMPOUND FOR ADJUSTING ACTIVITY OF NMDA RECEPTOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | BEIJING GREATWAY PHARMACEUTICAL TECHNOLOGY CO. LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230167076-A1 | 1,2,4-Oxadiazole Derivatives as Immunomodulators | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2023-06-01 | — | — | US | disclosed |
| EP-1692124-B1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | WYETH CORP (US) | 2008-10-15 | — | — | EP | disclosed |
| US-7420001-B2 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2008-09-02 | — | — | US | disclosed |
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-25 | — | — | US | disclosed |
| EP-1812383-A1 | GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | Smithkline Beecham Corporation (US) | 2007-08-01 | — | — | EP | disclosed |
| EP-1692124-A1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | Wyeth (US) | 2006-08-23 | — | — | EP | disclosed |
| WO-2006052722-A1 | GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-18 | — | — | WO | disclosed |
| WO-2005061477-A1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | WYETH (US) | 2005-07-07 | — | — | WO | disclosed |
| US-20050143422-A1 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
| US-5877030-A | REACTING AMINO ACID MOLECULES WITH REACTIVE XANTHENE DERIVATIVES, COMBINATORIAL LIBRARIES | SILICON VALLEY BANK | 1999-03-02 | — | — | US | disclosed |
| WO-1995019359-A1 | PROCESS FOR MAKING XANTHENE OR CUBANE BASED COMPOUNDS, AND PROTEASE INHIBITORS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1995-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348493-A1 | COMPOUND FOR ADJUSTING ACTIVITY OF NMDA RECEPTOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | GRIN1, GRIN3A, GRIN2C | SMN1; SMN2 567/4885CA14 3601/4885CA12 3159/4885 |
| US-20240218014-A1 | SYNTHESIS OF A CYCLIC PEPTIDE | VIP, QPCT, PTMS | SMN1; SMN2 4583/4885CA14 985/4885CA12 1550/4885 |
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | PYGM, PYGL, GYS1 | SMN1; SMN2 2240/4885CA14 2375/4885CA12 2507/4885 |
| US-20230167076-A1 | 1,2,4-Oxadiazole Derivatives as Immunomodulators | ARG1, IFNG, ICOS | SMN1; SMN2 4790/4885CA14 2113/4885CA12 2956/4885 |
| US-20050143422-A1 | Biaryl sulfonamides and methods for using same | STS, MMP3, AADAC | SMN1; SMN2 3220/4885CA14 405/4885CA12 206/4885 |
| US-20240400525-A1 | 1,2,4-Oxadiazole Derivatives as Immunomodulators | ARG1, IFNG, ICOS | SMN1; SMN2 4790/4885CA14 2113/4885CA12 2956/4885 |
| US-12037321-B2 | 1,2,4-oxadiazole derivatives as immunomodulators | ARG1, IFNG, ICOS | SMN1; SMN2 4790/4885CA14 2113/4885CA12 2956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.